Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer

Trial Profile

Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs Buparlisib (Primary) ; Olaparib (Primary)
  • Indications Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 25 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top